Novartis drug GlivecŪ shows significant overall survival benefit for patients with GIST after three years of adjuvant treatment vs. one year
Novartis announced new data today showing a significant improvement in both recurrence-free survival and overall survival for patients taking GlivecŪ (imatinib)* for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (GIST) compared to one year of treatment.
- (1888PressRelease) June 06, 2011 - These data will be presented at the 47th American Society of Clinical Oncology (ASCO) plenary session on Sunday, June 5.
Data show 66% recurrence-free survival and 92% overall survival at five years following three years of adjuvant therapy with Glivec in patients with resected KIT+ GIST[1]
First large Phase III clinical trial to demonstrate survival benefits of extended treatment with Glivec for three years compared to one year following surgery
Important finding for treatment of GIST patients who are at risk of recurrence following complete resection of primary tumor
The results show that at five years 66% of patients taking Glivec for three years remained free of cancer recurrence (primary endpoint) compared to 48% who had received Glivec for only one year (p
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam